[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].
Meshchaninov VN, Tkachenko EL, Zharkov SV et al. · Advances in gerontology = Uspekhi gerontologii · PMID 26390612
Study summary
Main finding
The report described changes in biological-age and nervous-system markers, alongside pro-oxidant activity and a decline in measured CD34-positive cells.
A small report studied Pinealon and Vesugen in adults with multiple conditions and an organic brain syndrome in remission.
What the researchers measured
Biological-age indicators, metabolic and cellular markers, oxidative activity, blood stem-cell markers, and chromatin condensation were assessed.
How to read this evidence
Researchers observed people or measured naturally occurring peptide levels. Associations do not show that administering the peptide caused a benefit.
Results in context
Changes in a biological-age score do not demonstrate longer life. The abstract reports potentially unfavorable marker changes and does not clearly establish a blinded randomized comparison; unchanged chromatin condensation is not comprehensive genetic safety evidence.
What this does not establish
Small clinical biomarker reports do not establish rejuvenation or genetic safety. The reported marker changes include potentially unfavorable findings.
Publication & source
Why this paper is included
A clinical report studied Pinealon and Vesugen in people with multiple illnesses; combined treatments limit attribution.